• About Us
    • Our Company
    • Leadership
    • Compliance
    • Contact
    • Medical Education Grants
  • Our
    Medicines
    • YCANTH
  • Product
    Candidates
    • Pipeline VP-102
    • Pipeline VP-103
    • Pipeline VP-315
    • R & D
    • Key Publications
  • Investors &
    Media
    • Investor Overview
    • Press Releases
    • Analyst Coverage
    • Presentations & Events
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Investor Connection
  • Careers
Menu
  • About Us
    • Our Company
    • Leadership
    • Compliance
    • Contact
    • Medical Education Grants
  • Our
    Medicines
    • YCANTH
  • Product
    Candidates
    • Pipeline VP-102
    • Pipeline VP-103
    • Pipeline VP-315
    • R & D
    • Key Publications
  • Investors &
    Media
    • Investor Overview
    • Press Releases
    • Analyst Coverage
    • Presentations & Events
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Investor Connection
  • Careers
For information about YCANTH® or to request a representative, visit YCANTHPro.com

SEC Filing Group: Other

25-SC 13G -20180625

16-EFFECT -20180614

1-D -20180221

newer →
About Us
  • Our Company
  • Leadership
  • Compliance
  • Contact
  • Medical Education Grants
Our Medicines
  • YCANTH
Product Candidates
  • Pipeline VP-102
  • Pipeline VP-103
  • Pipeline VP-315
  • R & D
  • Key Publications
Investors & Media
  • Investor Overview
  • Press Releases
  • Analyst Coverage
  • Presentations & Events
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investor FAQs
  • Investor Connection
Careers
  • Terms of Use
  • Privacy Policy
  • Patent Notices
VRCA_web
Twitter Linkedin-in Facebook-f
© 2025 Verrica Pharmaceuticals.